Prelude Therapeutics Incorporat (PRLD) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $4.97, but acceptable to hold if already in. Reasons: Market cap $396M below $400M minimum; Value-trap signals (3/5): Margin compression (op margin -240.5%), Material insider selling (4 sells, 0.03% of cap), Negative free cash flow.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative... Read more
Hold if already holding. Not a fresh buy at $4.97, but acceptable to hold if already in. Reasons: Market cap $396M below $400M minimum; Value-trap signals (3/5): Margin compression (op margin -240.5%), Material insider selling (4 sells, 0.03% of cap), Negative free cash flow. Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Market cap $396M below $400M minimum. Not in investable universe. Score 5.1/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 36d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $4.97, but acceptable to hold if already in. Reasons: Market cap $396M below $400M minimum; Value-trap signals (3/5): Margin compression (op margin -240.5%), Material insider selling (4 sells, 0.03% of cap), Negative free cash flow. Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Market cap $396M below $400M minimum. Not in investable universe. Target $6.80 (+36.8%), stop $4.62 (−7.6%), A.R:R 2.5:1. Score 5.1/10, moderate confidence.
Take-profit target: $6.80 (+36.8% upside). Target $6.80 (+36.8%), stop $4.62 (−7.6%), A.R:R 2.5:1. Stop-loss: $4.62.
Market cap $396M below $400M minimum; Value-trap signals (3/5): Margin compression (op margin -240.5%), Material insider selling (4 sells, 0.03% of cap), Negative free cash flow.
Prelude Therapeutics Incorporat trades at a P/E of N/A (forward -5.3). TrendMatrix value score: 5.4/10. Verdict: Hold.
9 analysts cover PRLD with a consensus score of 4.2/5. Average price target: $8.
What does Prelude Therapeutics Incorporat do?Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and...
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.